Record Nr. UNINA9910830979003321 Physiologically based pharmacokinetic modeling [[electronic resource]] **Titolo** : science and applications / / edited by Micaela B. Reddy ... [et al.] Pubbl/distr/stampa Hoboken, N.J., : Wiley-Interscience, c2005 **ISBN** 1-280-27583-9 9786610275830 0-470-24616-2 0-471-47876-8 0-471-47877-6 Descrizione fisica 1 online resource (442 p.) Altri autori (Persone) ReddyMicaela B Disciplina 615.7040724 615/.7 Soggetti **Pharmacokinetics** Xenobiotics Toxicology Lingua di pubblicazione Inglese **Formato** Materiale a stampa Livello bibliografico Monografia Description based upon print version of record. Note generali Nota di bibliografia Includes bibliographical references and index. Nota di contenuto PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING; CONTENTS; PREFACE: ACKNOWLEDGMENTS: CONTRIBUTORS: CHAPTER 1 INTRODUCTION: A HISTORICAL PERSPECTIVE OF THE DEVELOPMENT AND APPLICATIONS OF PBPK MODELS; 1.1 Introduction; 1.2 A Historical Perspective; 1.2.1 Responses to Inhaled Compounds; 1.2.2 Pharmaceutical Applications; 1.2.3 Occupational and Environmental Applications; 1.2.4 Digital Computation and PBPK Modeling; 1.3 Expansion of PBPK Model Applications: 1.3.1 PBPK Models for Tissue Dosimetry from Secondary Data; 1.3.2 Biological Mechanisms **Underlying Pharmacokinetic Behaviors** 1.3.3 Chemicals as Probes of Biological Processes1.3.4 Risk Assessment Applications; 1.3.5 PBPK Models as Repository of Mechanistic Data on Distribution and Response; 1.4 Summary; Notation; References; PART I PBPK MODELING FOR VOLATILE ORGANIC COMPOUNDS; CHAPTER 2 HALOGENATED ALKANES; 2.1 Introduction; 2.2 PBPK Model Development for Volatile Organics; 2.2.1 Model

Formulation; 2.2.2 Model Equations; 2.2.3 Model Parameterization; 2.2.4 Model Calculations; 2.3 Experimental Methods Demonstrated for Groups of Chemicals; 2.4 PBPK Models for Halogenated Alkanes; 2.4.1 **Anesthetic Gases** 2.4.2 Chlorofluorocarbons (CFCs), Refrigerants, and Halons2.4.3 Halogenated Alkanes; 2.5 Summary; Notation; References; CHAPTER 3 HALOGENATED ALKENES; 3.1 Introduction; 3.2 The Chloroethylenes: Background; 3.3 Review of PBPK Models; 3.3.1 Vinyl Chloride (VC); 3.3.2 Vinvl Fluoride (VF): 3.3.3 cis-1.2-Dichloroethylene (cDCE) and trans-1,2-Dichloroethylene (tDCE); 3.3.4 Vinylidene Chloride (VDC); 3.3.5 Trichloroethylene (TCE); 3.3.6 Tetrachloroethylene (PERC); 3.3.7 Allyl Chloride (AC); 3.3.8 b-Chloroprene (CD); 3.3.9 Hexachlorobutadiene, HCB; 3.4 Summary; Notation; References CHAPTER 4 ALKENE AND AROMATIC COMPOUNDS4.1 Introduction; 4.2 PK and Pharmacodynamic Properties Important in PBPK Model Development for Aromatic and Alkene Compounds; 4.2.1 Metabolism and Mode of Action; 4.2.2 Model Structures; 4.2.3 PK Differences; 4.2.4 Extrahepatic Metabolism and Transport of Metabolites; 4.2.5 GSH Conjugation: 4.2.6 Endogenous Production: 4.2.7 Reactivity with DNA and Protein; 4.2.8 Inhibition of Second Oxidative Steps; 4.2.9 Variability and PK Differences: 4.2.10 Subcompartments in PBPK Models: 4.2.11 "Privileged Access" of Epoxide Hydratase to Epoxide Substrates 4.3 Review of Aromatic and Alkene PBPK Models4.3.1 Benzene-A

## Sommario/riassunto

A definitive, single source of information on PBPK modelingPhysiologically-based pharmacokinetic (PBPK) modeling is becoming increasingly important in human health risk assessments and in supporting pharmacodynamic modeling for toxic responses. Organized by classes of compounds and modeling purposes so users can quickly access information, this is the first comprehensive reference of its kind. This book presents an overview of the underlying principles of PBPK model development. Then it provides a compendium of PBPK modeling information, including historical development, specific modeli

Known Human Carcinogen with an Uncertain Mode of Action; 4.3.2 Styrene-Early PBPK Models; 4.3.3 1,3-Butadiene; 4.3.4 Isoprene; 4.3.5 Ethylene, Propylene, and Their Oxides; 4.3.6 Naphthalene and Other PAHs; 4.3.7 Halobenzenes; 4.3.8 Miscellaneous Related Compounds; 4.4 Summary; Notation; References; CHAPTER 5 REACTIVE VAPORS IN

THE NASAL CAVITY; 5.1 Introduction; 5.1.1 Nasal Effects and Risk Assessment; 5.1.2 General Models for Nasal Uptake; 5.2 No Air-Phase

Models; 5.2.1 The "Perfused Nose" Model; 5.2.2 Vinyl Acetate

5.3 Creating the Air-Phase Compartments